Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Deferred Taxes: 2013-2023

Historic Deferred Taxes for Lineage Cell Therapeutics (LCTX) over the last 3 years, with Mar 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Deferred Taxes was N/A to -$1.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was -$4.1 million, marking a year-over-year change of. This contributed to the annual value of -$1.8 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q1 2023, Lineage Cell Therapeutics' Deferred Taxes is -$1.8 million, which was down 78.16% from -$1.0 million recorded in Q3 2021.
  • In the past 5 years, Lineage Cell Therapeutics' Deferred Taxes ranged from a high of -$200,000 in Q3 2020 and a low of -$4.4 million during Q1 2019.
  • In the last 2 years, Lineage Cell Therapeutics' Deferred Taxes had a median value of -$1.4 million in 2021 and averaged -$1.4 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first skyrocketed by 79.82% in 2020, then plummeted by 406.00% in 2021.
  • Over the past 4 years, Lineage Cell Therapeutics' Deferred Taxes (Quarterly) stood at -$991,000 in 2019, then surged by 79.82% to -$1.0 million in 2020, then plummeted by 406.00% to -$1.0 million in 2021, then reached -$1.8 million in 2023.
  • Its Deferred Taxes stands at -$1.8 million for Q1 2023, versus -$1.0 million for Q3 2021 and -$1.0 million for Q4 2020.